Illustrative image.

Rubraca

Name: Rubraca
Brand: Clovis Oncology
Availability: InStock

Rucaparib

Prescription required

$15420.00

200mg · 3 × 60 tablets · 3 months supply

BrandBranded medicine· By Clovis Oncology

$5140.00 per month

Strength

How long a supply?

1 month$5140.00 a monthOne-off$5140.00

3 months$5140.00 a monthOne-off$15420.00

6 months$5140.00 a monthOne-off$30840.00

Supplied from Israel

Test mode: no payment is taken. View cart

Annual cost

$61680a year at this pack size

Prescription required

Upload your prescription after ordering, or send it to our pharmacy team. We dispense only against a valid prescription.

200mg

250mg

300mg

About Rubraca

Overview

Rubraca (rucaparib) is a prescription medicine supplied as tablets. It is used as maintenance treatment for adults with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer associated with a harmful BRCA mutation, after a complete or partial response to platinum-based chemotherapy. It also treats adults with harmful BRCA mutation-associated prostate cancer that has spread and is resistant to testosterone-lowering treatment, following androgen receptor-directed therapy. Rubraca blocks PARP enzymes involved in DNA repair, which may lead to DNA damage and cancer cell death.

What it treats

- Maintenance treatment for adults with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer linked to a harmful inherited or acquired BRCA mutation, after a complete or partial response to platinum-based chemotherapy. - Treatment for adults with metastatic castration-resistant prostate cancer linked to a harmful inherited or acquired BRCA mutation, after androgen receptor-directed therapy. Patients are selected using an FDA-approved companion diagnostic test for Rubraca.

Safety information

Side effects

Common side effects of Rubraca include nausea, tiredness or weakness, vomiting, diarrhoea, reduced appetite, changes in taste, dizziness, shortness of breath and increased sensitivity to sunlight. Blood tests may show low red blood cells (anaemia), low platelets, low white blood cells, increased liver enzymes or increased creatinine. Other common side effects reported in patients with ovarian cancer include indigestion. In patients with BRCA-mutated prostate cancer, they also include muscle or bone pain, constipation, swelling, weight loss, abdominal pain, rash, problems with nerves outside the brain and spinal cord, urinary tract infection, cough, headache and bleeding. Serious side effects include myelodysplastic syndrome (MDS) and acute myeloid leukaemia (AML), serious bone marrow and blood disorders that can be fatal. Contact your doctor about persistent low blood counts or concerns about these conditions. Blood counts must be checked before treatment and monthly during treatment. Prolonged low blood counts require closer monitoring and may need specialist investigation. Rubraca must be stopped if MDS or AML is confirmed. Rubraca can harm an unborn baby. Contact your doctor if you become pregnant during treatment.

When to call your doctor

- Shortness of breath: seek medical attention immediately. - Unusual bleeding: seek medical attention immediately. - Severe tiredness, weakness or dizziness: seek medical attention immediately.

If symptoms are severe or getting worse quickly, seek emergency care rather than waiting.

Before taking this medicine

The FDA label lists no contraindications for Rubraca. However, important warnings and precautions apply: Rubraca can cause myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), serious blood and bone marrow disorders that can be fatal. Treatment should not begin until blood-related side effects from previous chemotherapy have sufficiently resolved. Blood counts must be checked before treatment and monthly during treatment. Persistent abnormalities may require treatment changes, closer monitoring and specialist assessment. Rubraca must be stopped if MDS or AML is confirmed. Rubraca can harm an unborn baby. Women who could become pregnant should use effective contraception during treatment and for 6 months after the last dose. Men with partners who could become pregnant or who are pregnant should use effective contraception during treatment and for 3 months after the last dose. Women should not breastfeed while taking Rubraca.

Interactions

Rubraca can increase blood levels of certain medicines processed by the liver enzymes CYP1A2, CYP3A, CYP2C9 or CYP2C19, which may make their side effects more frequent or severe. Ask your doctor to review your other medicines; some may need a dose adjustment. Tell your doctor if you take warfarin. If it must be used with Rubraca, more frequent INR blood tests to monitor blood clotting may be needed.

Using Rubraca

Dosing

Dosing is set by your prescriber. Each health care professional may prescribe medication differently according to a patient's medical history and condition, so follow the directions on your prescription label and speak to your doctor or pharmacist before changing anything.

Storage

Store below 25°C in a dry place, in the original pack, away from direct light and moisture. Do not keep it in a bathroom. Keep all medicines out of the sight and reach of children.

Clinical information on this page is summarised from the US FDA label RUBRACA (RUCAPARIB) TABLET, FILM COATED [PHARMAAND GMBH] (DailyMed, retrieved 19 September 2026).

Reviews

No reviews yet. Mail Order Drugs opened recently, and we publish reviews only from verified customers of this site, so this space stays empty until real ones arrive.